Trial Radar AI | ||
|---|---|---|
De klinische studie NCT05327452 voor Borstkanker, Colorectale kanker, prostaatkanker is recruterend. Bekijk de kaartweergave van de Klinische Studies Radar en de AI-ontdekkingstools voor alle details. Of stel hier een vraag. | ||
Eén studie komt overeen met de filtercriteria
Kaartweergave
Testing Home-based Exercise Strategies in Underserved Minority Cancer Patients Undergoing Chemotherapy: the THRIVE Study
Informatie over klinische studies is voornamelijk in het Engels beschikbaar. Trial Radar AI kan echter helpen! Klik op 'Leg studie uit' om de informatie over de studie te bekijken en te bespreken in de taal van uw keuze.
De klinische studie NCT05327452 is een interventioneel studie bij Borstkanker, Colorectale kanker, prostaatkanker met de status recruterend. Het doel is om 135 deelnemers te includeren vanaf 31 oktober 2022. De studie wordt geleid door Dana-Farber Cancer Institute en de voltooiing is gepland op 31 mei 2026. Laatste update op ClinicalTrials.gov: 23 september 2025.
Beknopte samenvatting
The purpose of this research is to determine whether a 16 week, home-based, aerobic and resistance exercise intervention will increase physical activity levels in Black and Hispanic breast, colorectal, or prostate cancer patients.
The names of the study interventions involved in this study are:
- Supervised aerobic and resistance exercise (SUP) - virtually supervised 16- week aerobic and resistance exercise performed at home via Zoom.
- Unsupervised aerobic and resistance exercise (UNSUP) - home-based 16- week aerobic and resistance exercise.
- Attention control (AC) - 16-week home-based stretching.
Uitgebreide beschrijving
This is a randomized control trial of Black and Hispanic patients who have been newly diagnosed with breast, colorectal, or prostate cancer and are being prescribed chemotherapy to determine the effects of home-based exercise on levels of physical activity. It will also evaluate the impact of home-based exercise on cardiovascular (heart health) risk factors.
The research study procedures include: screening for eligibility and study treatment including evaluations of body composition, blood tests, fitness and strength assessments, and surveys at study entry and follow-up visits.
Participants in this study will be randomly assigned to one of three groups: 1) Supervised aerobic and resistance exercise (SUP), 2) Unsupervised aerobic and resistance exercise (UNSUP), or 3) Attention control (AC).
Participation is expected to last for 8 months.
It is expected that about 135 people will take part in this research study.
Officiële titel
Testing Home-based Exercise Strategies to Improve Exercise Participation and Cardiovascular Health in Underserved Minority Patients With Cancer Undergoing Chemotherapy: the THRIVE Study
Aandoeningen
BorstkankerColorectale kankerprostaatkankerPublicaties
Wetenschappelijke artikelen en onderzoekspapers gepubliceerd over deze klinische studie:Andere studie-ID's
NCT-ID
Startdatum (Werkelijk)
2022-10-31
Laatste update geplaatst
2025-09-23
Verwachte einddatum
2026-05-31
Inschrijving (Geschat)
135
Studietype
Interventioneel
FASE
N.v.t.
Status
Recruterend
Trefwoorden
Breast Cancer
Colorectal Cancer
Prostate Cancer
Colorectal Cancer
Prostate Cancer
Primaire doel
Ondersteunende zorg
Toewijzing
Gerandomiseerd
Interventiemodel
Parallel
Blindering
Geen (Open-label)
Armen / Interventies
| Deelnemersgroep/Studiearm | Interventie/Behandeling |
|---|---|
ExperimenteelSupervised aerobic and resistance exercise (SUP) Participants will be randomly assigned to receive 3x weekly at home, virtually supervised aerobic and resistance exercise sessions with a certified exercise trainer for 16 weeks.
Participants will also have a baseline test, mid intervention cardiovascular and strength tests and one postintervention and one follow up visit. | Supervised Home-based Exercise Online supervised aerobic and resistance exercise |
ExperimenteelUnsupervised aerobic and resistance exercise (UNSUP) Participants will be randomly assigned to receive 3x weekly at home, unsupervised aerobic and resistance exercise sessions with a 1x weekly telehealth call with a certified exercise trainer for 16 weeks.
Participants will also have a baseline test, mid intervention cardiovascular and strength tests and one postintervention and one follow up visit. | Unsupervised Home-based Exercise Unsupervised aerobic and resistance exercise (UNSUP) |
Actieve comparatorAttention Control (AC) Participants will be randomly assigned to receive 3x weekly at home stretching exercise for 16 weeks.
Participants will also have a baseline test, mid intervention cardiovascular and strength tests and one postintervention and one follow up visit. | Aandachtscontrole Stretching Program |
Primaire uitkomst
Secundaire uitkomst
| Uitkomstmaat | Beschrijving van de uitkomstmaat | Tijdsbestek |
|---|---|---|
Change in Physical Activity Participation | Changes from baseline in physical activity participation measured by Godin Leisure-Time Exercise Questionnaire. | Evaluated at week 1 for baseline, week 16 for post-intervention assessment, and week 32 for follow-up |
| Uitkomstmaat | Beschrijving van de uitkomstmaat | Tijdsbestek |
|---|---|---|
Biomarkers for Cardiovascular and Metabolic Health - insulin | Fasting blood will be drawn from the antecubital vein by a trained phlebotomist. Insulin will be measured. | Evaluated at week 1 for baseline, week 16 for post-intervention assessment, and week 32 for follow-up |
Blood Pressure | Blood pressure will be assessed using an automated blood pressure cuff to measure both systolic and diastolic blood pressure. | Evaluated at week 1 for baseline, week 16 for post-intervention assessment, and week 32 for follow-up |
Body Composition | Body composition (lean mass and fat mass) will be assessed via bioelectrical impedance using a validated scale. | Evaluated at week 1 for baseline, week 16 for post-intervention assessment, and week 32 for follow-up |
Cardiopulmonary Fitness | Cardiopulmonary fitness will be measured by a submaximal graded exercise cycling test. | Evaluated at week 1 for baseline, week 9 for mid-point, week 16 for post-intervention assessment, and week 32 for follow-up |
Physical Fitness | Physical Fitness will be measured by the short physical performance battery (SPPB). | Evaluated at week 1 for baseline, week 16 for post-intervention assessment, and week 32 for follow-up |
Cardiorespiratory Fitness | Cardiorespiratory fitness will be assessed by the 6-minute walk test. | Evaluated at week 1 for baseline, week 16 for post-intervention assessment, and week 32 for follow-up |
Muscular Strength | Muscular strength will be assessed with a 10 repetition maximum test. | Evaluated at week 1 for baseline, week 9 for mid-point, week 16 for post-intervention assessment, and week 32 for follow-up |
Patient Reported Outcomes - Quality of Life | Quality of life will be assessed by EORTC QLQ C-30. | Evaluated at week 1 for baseline, week 16 for post-intervention assessment, and week 32 for follow-up |
Patient Reported Outcomes - Health-related domains | Health-related domains of patient reported outcomes will be assessed by PROMIS-29 Profile v2.1. | Evaluated at week 1 for baseline, week 16 for post-intervention assessment, and week 32 for follow-up |
Patient Reported Outcomes - Sleep | Quality of life will be assessed by the Pittsburg Sleep Quality Index (PSQI). | Evaluated at week 1 for baseline, week 16 for post-intervention assessment, and week 32 for follow-up |
Patient Reported Outcomes - Symptoms | Symptomatic toxicities will be assessed by PRO-CTCAE. | Evaluated at week 1 for baseline, week 16 for post-intervention assessment, and week 32 for follow-up |
Dietary Assessment | Dietary recall will be used to assess recent dietary patterns for two weekdays and one weekend day using NutriBase 11. | Evaluated at week 1 for baseline, week 16 for post-intervention assessment, and week 32 for follow-up |
Acceptability of Intervention Questionnaire Ratings | Intervention acceptability and feasibility will be assessed via Acceptability of Intervention and Feasibility of Intervention questionnaires. Items are measured on a 5-point Likert scale (completely disagree to completely agree). Score is calculated mean. An average rating of 4 or higher will be considered feasible/acceptable. | Evaluated at months 2 and 4 |
Feasibility of Intervention Questionnaire Ratings | Intervention acceptability and feasibility will be assessed via Acceptability of Intervention and Feasibility of Intervention questionnaires. Items are measured on a 5-point Likert scale (completely disagree to completely agree). Score is calculated mean. An average rating of 4 or higher will be considered feasible/acceptable. | Evaluated at months 2 and 4 |
Augmentation Index | Augmentation index (a marker for arterial stiffness) will also be assessed using Mobil-O-Graph device. | Time Frame: Evaluated at week 1 for baseline, week 16 for post-intervention assessment, and week 32 for follow-up |
Biomarkers for Cardiovascular and Metabolic Health - glucose | Fasting blood will be drawn from the antecubital vein by a trained phlebotomist. Glucose will be measured. | Evaluated at week 1 for baseline, week 16 for post-intervention assessment, and week 32 for follow-up |
Biomarkers for Cardiovascular and Metabolic Health - HbA1c | Fasting blood will be drawn from the antecubital vein by a trained phlebotomist. HbA1c will be measured. | Evaluated at week 1 for baseline, week 16 for post-intervention assessment, and week 32 for follow-up. |
Biomarkers for Cardiovascular and Metabolic Health - c-peptide | Fasting blood will be drawn from the antecubital vein by a trained phlebotomist. C-peptide (biomarkers of glycemic control and insulin resistance) will be measured. | Evaluated at week 1 for baseline, week 16 for post-intervention assessment, and week 32 for follow-up. |
Biomarkers for Cardiovascular and Metabolic Health - c-reactive protein | Fasting blood will be drawn from the antecubital vein by a trained phlebotomist. C-reactive protein (CRP; biomarker of system inflammation) will be measured. | Evaluated at week 1 for baseline, week 16 for post-intervention assessment, and week 32 for follow-up. |
Geschiktheidscriteria
Leeftijd van deelnemers
Volwassene, Oudere volwassene
Minimumleeftijd
18 Years
Geslachten die in aanmerking komen voor de studie
Allen
- Over 18 years old; children under the age of 18 will be excluded due to rarity of disease
- Newly diagnosed with stage I-III breast, colorectal or prostate cancer
- Self-identify as Hispanic or Black
- Are within 4 weeks of initiating chemotherapy
- Overweight or obese (BMI >25kg/m2 or body fat percent >30)
- Physician's clearance to participate in moderate-vigorous intensity exercise
- Speak English or Spanish
- Engaging in less than 90 minutes of moderate-or-vigorous physical activity per week
- Willing to travel to Dana-Farber Cancer Institute for necessary data collection
- Ability to understand and the willingness to sign a written informed consent document.
- Pre-existing musculoskeletal or cardiorespiratory conditions
- Patients should not have any uncontrolled illness including ongoing or active infection, uncontrolled diabetes, hypertension, or thyroid disease
- Patients with other active malignancies
- Patients with metastatic disease
- Participate in more than 90 minutes of structured exercise/week
- Unable to travel to Dana-Farber Cancer Institute for necessary data collection
- Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study.
Dana-Farber Cancer Institute- Nationaal Kankerinstituut, VS3028 actieve klinische studies om te verkennen
- University of Massachusetts, Boston
Verantwoordelijke instantie
Christina Dieli-Conwright, PhD, Hoofdonderzoeker, Principal Investigator, Dana-Farber Cancer Institute
Centraal Contactpersoon
Contact: Christina Dieli-Conwright, PhD, MPH, 617-582-8321, [email protected]
Contact: Mary Norris, MSc, 8572150195, [email protected]
2 Studielocaties in 1 landen
Massachusetts
Brigham and Women's Hospital, Boston, Massachusetts, 02115, United States
Christina Dieli-Conwright, PhD, MPH, Contact, 617-582-8321, [email protected]
Christina Dieli-Conwright, PhD, MPH, Hoofdonderzoeker
Recruterend
Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States
Christina Dieli-Conwright, PhD, MPH, Contact, 617-632-3800, [email protected]
PhD, MPH, Contact
Christina Dieli-Conwright, PhD, Hoofdonderzoeker
Recruterend